Home – Safe Biologics

[et_pb_section fb_built=”1″ _builder_version=”4.20.4″ _module_preset=”default” custom_padding=”2px||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.4″ _module_preset=”default” width=”100%” max_width=”100%” custom_padding=”0px||1px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_slider include_categories=”5″ more_text=”Learn More” show_meta=”off” use_text_overlay=”on” text_overlay_color=”rgba(3,0,49,0.65)” text_border_radius=”0px” _builder_version=”4.20.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#c8202d” button_border_width=”0px” button_border_color=”#c8202d” button_border_radius=”0px” button_alignment=”left” custom_padding=”150px||150px||true|false” hover_enabled=”0″ global_colors_info=”{}” arrows_custom_color=”#FFFFFF” dot_nav_custom_color=”#FFFFFF” text_orientation=”left” body_font=”Lato||||||||” body_font_size=”20px” body_line_height=”1.9em” sticky_enabled=”0″ auto=”on” auto_speed=”4000″][/et_pb_post_slider][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.4″ _module_preset=”default” custom_padding=”100px||100px||true|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.4″ _module_preset=”default” header_2_font=”Lato|||on|||||” header_2_text_align=”center” header_2_text_color=”#C8202D” header_2_font_size=”18px” header_2_letter_spacing=”3px” global_colors_info=”{}”]

More News

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.20.4″ _module_preset=”default” width=”100%” max_width=”1125px” custom_padding=”0px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blog fullwidth=”off” posts_number=”3″ include_categories=”5″ show_more=”on” show_author=”off” show_date=”off” show_categories=”off” show_pagination=”off” offset_number=”4″ _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato||||||||” header_text_color=”#000000″ header_font_size=”30px” header_line_height=”1.1em” body_font=”Lato||||||||” body_text_color=”#000000″ body_font_size=”15px” read_more_font=”|||on|||||” read_more_text_color=”#C8202D” read_more_font_size=”15px” read_more_letter_spacing=”1px” read_more_line_height=”2.5em” border_color_all=”RGBA(255,255,255,0)” global_colors_info=”{}”][/et_pb_blog][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.4″ _module_preset=”default” background_color=”rgba(0,0,0,0.38)” background_image=”https://safebiologics.wpengine.com/wp-content/uploads/2023/06/red-cells-scaled.jpg” background_blend=”multiply” custom_padding=”111px||111px||true|” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Biosimilars” content_max_width=”920px” _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato||||||||” header_font_size=”3em” body_font=”Lato||||||||” body_font_size=”20px” body_line_height=”1.9em” background_enable_image=”off” text_orientation=”center” background_layout=”dark” module_alignment=”center” global_colors_info=”{}”]Biosimilars 101
Biologic medicines are used to treat millions of patients with serious illnesses like cancer, arthritis, and psoriasis. The patents for many biologic therapies are expiring, and biosimilars are entering the marketplace. These give patients new treatment options, and reduce costs through competition. Regulatory authorities around the world have put policies in place to ensure that biosimilars have been appropriately tested, and are safe and effective for patients.

Non-Medical Switching
Non-Medical Switching is when a patient is switched from one biologic medicine (either an originator product or a biosimilar) to another product- not for reasons of health or safety but for economic reasons. This is often done by a third party such as a private insurer, a pharmacy-benefit manager, or a government agency in order to save money, increase profits, or because of a deal made with a particular manufacturer. This practice is controversial among patients and physicians because treatment decisions are not “one size fits all”. Many patients try several biologic medicines until they find one that stabilizes their condition; physicians generally oppose the unnecessary switching of medicines for stable patients.[/et_pb_blurb][et_pb_button button_text=”Learn MOre” button_alignment=”center” _builder_version=”4.20.4″ _module_preset=”default” custom_button=”on” button_text_size=”15px” button_text_color=”#FFFFFF” button_bg_color=”#c8202d” button_border_color=”#c8202d” button_border_radius=”0px” button_letter_spacing=”0px” button_font=”|700||on|||||” background_layout=”dark” global_colors_info=”{}”][/et_pb_button][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.4″ _module_preset=”default” background_image=”https://safebiologics.wpengine.com/wp-content/uploads/2023/06/bg-bw-scaled.jpg” custom_padding=”177px||177px||true|” global_colors_info=”{}”][et_pb_row column_structure=”1_3,2_3″ _builder_version=”4.20.4″ _module_preset=”default” background_color=”#c8202d” width=”60%” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.4″ _module_preset=”default” text_text_color=”#FFFFFF” text_font_size=”40px” text_line_height=”1.1em” header_2_text_align=”center” header_2_text_color=”#FFFFFF” header_2_font_size=”27px” custom_padding=”60px|46px|60px|46px|true|true” global_colors_info=”{}”]Member Partners[/et_pb_text][/et_pb_column][et_pb_column type=”2_3″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.4″ _module_preset=”default” text_text_color=”#FFFFFF” text_font_size=”18px” text_line_height=”1.9em” custom_padding=”|50px||50px|false|true” global_colors_info=”{}”]

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups and individuals—from patients to physicians, biotechnology companies that develop innovative and biosimilar medicines and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

Learn more

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.20.4″ _module_preset=”default”][et_pb_column _builder_version=”4.20.4″ _module_preset=”default” type=”4_4″][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row column_structure=”1_6,1_6,1_6,1_6,1_6,1_6″ use_custom_gutter=”on” _builder_version=”4.20.4″ _module_preset=”default” width=”100%” max_width=”1298px” global_colors_info=”{}”][et_pb_column type=”1_6″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https://safebiologics.wpengine.com/wp-content/uploads/2023/06/logo-footer.png” title_text=”logo-footer” _builder_version=”4.20.4″ _module_preset=”default” custom_margin=”||15px|||” global_colors_info=”{}”][/et_pb_image][et_pb_text _builder_version=”4.20.4″ _module_preset=”default” text_font=”Lato||||||||” text_font_size=”12px” text_line_height=”1.6em” global_colors_info=”{}”]The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups — from patients to physicians, medical innovators, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.

Contact Us[/et_pb_text][/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Who We Are” _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato|700||on|||||” header_text_color=”#12485b” header_font_size=”14px” body_text_color=”#12485b” body_font_size=”13px” body_line_height=”2.4em” global_colors_info=”{}”]About Us
Leadership
Member Partners
International Advisory Board[/et_pb_blurb][/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Latest News” _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato|700||on|||||” header_text_color=”#12485b” header_font_size=”14px” body_text_color=”#12485b” body_font_size=”13px” body_line_height=”2.4em” global_colors_info=”{}”]Latest News
Letters
Newsletter
Press Releases
Recent Events[/et_pb_blurb][/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”The Issue” _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato|700||on|||||” header_text_color=”#12485b” header_font_size=”14px” body_text_color=”#12485b” body_font_size=”13px” body_line_height=”2.4em” global_colors_info=”{}”]About the Issue
FAQs
Naming
Substitution Policy
Biologic Safety
BIO Principles[/et_pb_blurb][/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Policy” _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato|700||on|||||” header_text_color=”#12485b” header_font_size=”14px” body_text_color=”#12485b” body_font_size=”13px” body_line_height=”2.4em” global_colors_info=”{}”]Australia
Canada
European Union
FDA
FDA Guidance
In the States[/et_pb_blurb][/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.20.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Resourves” _builder_version=”4.20.4″ _module_preset=”default” header_font=”Lato|700||on|||||” header_text_color=”#12485b” header_font_size=”14px” body_text_color=”#12485b” body_font_size=”13px” body_line_height=”2.4em” global_colors_info=”{}”]Surveys
Courses
Webinars[/et_pb_blurb][/et_pb_column][/et_pb_row][/et_pb_section]

Latest News

April 2024 Newsletter

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the […]

March 2024 Newsletter

Biden Administration HHS Budget Would Permit Third-Party Substitution of All Biosimilars On March 11th, the Biden Administration released its FY25 HHS Budget. In response, ASBM Executive Director Michael Reilly published a blog post sharing his concerns with the Administration’s proposal to permit widespread automatic (pharmacy-level) substitution of all biosimilars in place of their reference products; without physician approval […]

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars

In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the way generics are. Doing so would undermine physician confidence in biosimilars and jeopardize treatment stability for many […]